Incretin-based therapies for patients with type 1 diabetes: a meta-analysis

摘要: Objective Combined treatment with an incretin-based drug, such as a glucagon-like peptide 1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor, and basal insulin is new strategy for improving glucose control in type diabetes mellitus (T1DM). We performed meta-analysis to assess the effect of this combined on glycaemic control, dose, severe hypoglycaemia, weight gain gastrointestinal side effects T1DM patients. Methods searched PubMed, EMBASE Cochrane Library relevant studies published before July 16, 2018. The primary outcome was glycosylated haemoglobin (HbA1c). Secondary outcomes included total daily body weight, hypoglycaemia effects. Results Nine randomized controlled trials (RCTs) involving 2389 patients were ultimately meta-analysis. pooled data suggested that therapy associated reduction HbA1c levels (weighted mean difference (WMD) -0.17%, 95% confidence interval (CI) -0.24 -0.11, P < 0.001), dose (WMD -5.53 IU/day, CI -8.89 -2.17, = 0.001) -3.24 kg, -4.43 -2.04, 0.001). Incretins did not increase risk (odds ratio (OR) 0.83, 0.60-1.16, 0.287) but increased occurrence (OR 3.46, 2.20-5.45, Conclusions In patients, GLP-1 RAs, DPP-4 inhibitors, appear be effective may